MCID: HYP073
MIFTS: 43

Hypersensitivity Reaction Type Iv Disease

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Hypersensitivity Reaction Type Iv Disease

MalaCards integrated aliases for Hypersensitivity Reaction Type Iv Disease:

Name: Hypersensitivity Reaction Type Iv Disease 12 15
Immunoproliferative Disorders 44 70
Immunoproliferative Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2916
MeSH 44 D007160
SNOMED-CT 67 127071007
ICD10 32 C88 C88.9
UMLS 70 C0021070

Summaries for Hypersensitivity Reaction Type Iv Disease

Disease Ontology : 12 A hypersensitivity reaction disease that is characterized by a cell-mediated response to antigens, where Th1 helper T cells react with antigens on antigen-presenting cells and cause a delayed type immune response.

MalaCards based summary : Hypersensitivity Reaction Type Iv Disease, also known as immunoproliferative disorders, is related to cryoglobulinemia and autoimmune lymphoproliferative syndrome. An important gene associated with Hypersensitivity Reaction Type Iv Disease is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Dexamethasone and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include t cells, kidney and b cells, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Related Diseases for Hypersensitivity Reaction Type Iv Disease

Diseases in the Hypersensitivity Reaction Type Iv Disease family:

Hypersensitivity Reaction Type Iii Disease

Diseases related to Hypersensitivity Reaction Type Iv Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 862)
# Related Disease Score Top Affiliating Genes
1 cryoglobulinemia 32.6 TNF IL6 IFNG
2 autoimmune lymphoproliferative syndrome 32.0 TNF IL2 IL10 ICOSLG FASLG FAS
3 sarcoidosis 1 32.0 TNF SERPINA3 NOD2 MIR155 IL2 IFNG
4 intestinal disease 30.7 SERPINA3 MIR155 ICOSLG CCR6
5 post-transplant lymphoproliferative disease 30.6 TNF IL6 IL10
6 monoclonal gammopathy of uncertain significance 30.6 TNF IL6 ICOSLG CCR6
7 duodenitis 30.6 TNF CRP CD8A CD4
8 polyneuropathy 30.5 TNF IL6 CRP ACE
9 amyloidosis 30.4 TNF SERPINA3 IL6 CRP
10 deficiency anemia 30.2 TNF SERPINA3 IL6 ICOSLG CRP CD8A
11 lymphoma, non-hodgkin, familial 30.0 SERPINA3 MIR155 IL6 IL2 ICOSLG FAS
12 crohn's disease 30.0 TNF NOD2 IL6 IL2 IL10 IFNG
13 heavy chain disease 11.3
14 schnitzler syndrome 11.3
15 chronic nk-cell lymphocytosis 11.3
16 acute dacryoadenitis 10.6 CRP ACE
17 cork-handlers' disease 10.6 CD8A CD4
18 adult acute lymphocytic leukemia 10.6 CD8A CD4 CCR6
19 brawny scleritis 10.6 IFNG ACE
20 mediastinum teratoma 10.6 CRP ACE
21 punctate inner choroidopathy 10.6 TNF IL10
22 sigmoid disease 10.6 TNF NOD2
23 cardiac tuberculosis 10.6 CRP ACE
24 external pathological resorption 10.6 TNF IL6
25 early yaws 10.5 CD8A CD4
26 esophageal candidiasis 10.5 CD8A CD4 CCR6
27 type 1 diabetes mellitus 23 10.5 TNF CD8A CD4
28 tropical endomyocardial fibrosis 10.5 TNF IL10
29 drug reaction with eosinophilia and systemic symptoms 10.5 TNF CRP
30 anterior scleritis 10.5 TNF CRP ACE
31 posterior scleritis 10.5 TNF CRP ACE
32 scorpion envenomation 10.5 TNF IL6
33 physiological polycythemia 10.5 TNF IL6
34 autoimmune cholangitis 10.5 CD8A CD4 CCR6
35 neuroretinitis 10.5 CRP CD4 ACE
36 ventilation pneumonitis 10.5 CD8A CD4
37 optic papillitis 10.5 CRP CD4 ACE
38 necrotic uveal melanoma 10.5 IFNG CD8A CD4
39 immunodeficiency with hyper-igm, type 3 10.5 ICOSLG CD8A CD4
40 rheumatoid arthritis interstitial lung disease 10.5 TNF CRP CD4
41 inflammatory bowel disease 5 10.5 NOD2 ICOSLG CCR6
42 ocular tuberculosis 10.5 IFNG CD4 ACE
43 cat-scratch disease 10.5 CRP CD4 ACE
44 primary syphilis 10.5 CRP CD8A CD4
45 pneumonic plague 10.5 TNF CD8A CD4
46 toxic megacolon 10.5 TNF CRP CCR6
47 autoimmune lymphoproliferative syndrome, type iia 10.5 CD8A CD4 CASP10
48 meningovascular neurosyphilis 10.5 TNF CRP CD4
49 toxicodendron dermatitis 10.5 TNF IL2 CD8A
50 bartonellosis 10.5 CRP CD4 ACE

Graphical network of the top 20 diseases related to Hypersensitivity Reaction Type Iv Disease:



Diseases related to Hypersensitivity Reaction Type Iv Disease

Symptoms & Phenotypes for Hypersensitivity Reaction Type Iv Disease

MGI Mouse Phenotypes related to Hypersensitivity Reaction Type Iv Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.1 ACE CCR6 CD4 CD8A FAS FASLG
2 endocrine/exocrine gland MP:0005379 10.07 ACE CD4 CD8A FAS FASLG IFNG
3 immune system MP:0005387 10.07 ACE CCR6 CD4 CD8A CRP FAS
4 digestive/alimentary MP:0005381 10.06 CD4 FAS FASLG IFNG IL10 IL2
5 integument MP:0010771 9.81 CD4 CD8A FAS FASLG IFNG IL10
6 liver/biliary system MP:0005370 9.56 ACE FAS FASLG IFNG IL10 IL2
7 neoplasm MP:0002006 9.23 ACE FAS FASLG IFNG IL10 IL2

Drugs & Therapeutics for Hypersensitivity Reaction Type Iv Disease

Drugs for Hypersensitivity Reaction Type Iv Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 20)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
2
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
4
Gemcitabine Approved Phase 2 95058-81-4 60750
5
rituximab Approved Phase 2 174722-31-7 10201696
6
Blinatumomab Approved, Investigational Phase 2 853426-35-4
7 Immunoglobulins Phase 2
8 Antibodies Phase 2
9 Antibodies, Bispecific Phase 2
10 Immunoglobulins, Intravenous Phase 2
11 gamma-Globulins Phase 2
12 Rho(D) Immune Globulin Phase 2
13 Vaccines Phase 2
14
Fludarabine Approved Phase 1 21679-14-1, 75607-67-9 30751
15
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
16 Immunologic Factors Phase 1
17 Immunosuppressive Agents Phase 1
18 Antirheumatic Agents Phase 1
19 Alkylating Agents Phase 1
20 Bendamustine Hydrochloride Phase 1

Interventional clinical trials:

(show all 11)
# Name Status NCT ID Phase Drugs
1 A Non-randomized, Open-label, Phase II Study of Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not Suitable for Transplantation Unknown status NCT03373019 Phase 2 Chidamide combined with R-GDP
2 An Open Label, Multicenter, Phase II Study to Evaluate Efficacy and Safety of the BiTE® Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) Completed NCT01466179 Phase 2
3 Study of Immune Responses and Safety of Recombinant CD40 Ligand in Patients With X-Linked Hyper IgM Syndrome Completed NCT00001145 Phase 2 Bacteriophage;rhuCD40L;KLH
4 Administration of Autologous CAR-T Cells Targeting the CD19 Antigen and Containing the Inducible caspase9 Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Recruiting NCT03016377 Phase 1, Phase 2 Rimiducid;Cyclophosphamide;Fludarabine
5 A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting Recruiting NCT03744676 Phase 2
6 Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma Recruiting NCT02690545 Phase 1, Phase 2
7 A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting. Recruiting NCT04309084 Phase 1, Phase 2
8 Phase I Study of the Administration of T Lymphocytes Co-Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin Lymphoma and Cutaneous T-Cell Lymphoma Recruiting NCT03602157 Phase 1 Bendamustine;Fludarabine
9 A Phase I Study of Autologous Activated T-cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Relapsed/Refractory B-cell Lymphoma Recruiting NCT03696784 Phase 1 Bendamustine;Fludarabine;AP1903;Cyclophosphamide
10 Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS) Recruiting NCT02663297 Phase 1 ATLCAR.CD30 cells
11 Compassionate Use Administration of Autologous CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch No longer available NCT03594162 iC9-CAR19 cells;AP1903;Cyclophosphamide;Fludarabine

Search NIH Clinical Center for Hypersensitivity Reaction Type Iv Disease

Cochrane evidence based reviews: immunoproliferative disorders

Genetic Tests for Hypersensitivity Reaction Type Iv Disease

Anatomical Context for Hypersensitivity Reaction Type Iv Disease

MalaCards organs/tissues related to Hypersensitivity Reaction Type Iv Disease:

40
T Cells, Kidney, B Cells

Publications for Hypersensitivity Reaction Type Iv Disease

Articles related to Hypersensitivity Reaction Type Iv Disease:

(show top 50) (show all 52)
# Title Authors PMID Year
1
"Role Of Stereotactic Radiosurgery In Intracranial Histiocytosis: A Systematic Review Of Literature Of An Emerging Modality For Localized Disease". 61
33744421 2021
2
Screening for Humoral Immunodeficiency in Patients with Community-Acquired Pneumonia. 61
30534641 2019
3
Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity. 61
28350808 2017
4
Gammaherpesvirus latency induces antibody-associated thrombocytopenia in mice. 61
23245703 2013
5
CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma. 61
23161721 2012
6
Enhanced serological diagnosis of invasive meningococcal disease by determining anti-group C capsule IgM antibody by enzyme immunoassay. 61
16175899 2005
7
Spontaneous outgrowth of EBV-transformed B-cells reflects EBV-specific immunity in vivo; a useful tool in the follow-up of EBV-driven immunoproliferative disorders in allograft recipients. 61
14652716 2004
8
A flow cytometry technique to study nuclear factor-kappa B (NFkappaB) translocation during human B cell activation. 61
14611907 2003
9
The structure of an entire noncovalent immunoglobulin kappa light-chain dimer (Bence-Jones protein) reveals a weak and unusual constant domains association. 61
10091599 1999
10
Expression and regulation of mRNA for distinct isoforms of cAMP-specific PDE-4 in mitogen-stimulated and leukemic human lymphocytes. 61
9515164 1998
11
Molecular modeling of immunoglobulin light chains implicates hydrophobic residues in non-amyloid light chain deposition disease. 61
9488143 1997
12
11q13 rearrangement in B cell chronic lymphocytic leukemia. 61
9250825 1997
13
[Anemia and hemostasis dysfunction in patients with immunoproliferative disorders]. 61
7561364 1995
14
[Various immunoproliferative disorders]. 61
7561367 1995
15
[Nerve lesions in patients with immunoproliferative disorders]. 61
7561361 1995
16
Effect of alpha IFN on unaggressive immunoproliferative disorders. 61
7758989 1995
17
Monoclonal immunoglobulin deposition disease: a review of immunoglobulin chain alterations. 61
7927989 1994
18
Preferential expression of human lambda-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenström's macroglobulinemia. 61
8181187 1994
19
Paraproteinemic crystalloidal keratopathy: an ultrastructural study of two cases, including immunoelectron microscopy. 61
8122330 1993
20
Monoclonal Ig L chain and L chain V domain fragment crystallization in myeloma-associated Fanconi's syndrome. 61
8468490 1993
21
[Heavy chain diseases]. 61
8502962 1993
22
Atypical immunoproliferative disorders: when of age? 61
8506619 1993
23
Structurally abnormal immunoglobulins in human immunoproliferative disorders. 61
1571535 1992
24
The spontaneous apoptotic cell death of normal human lymphocytes in vitro: the release of, and immunoproliferative response to, nucleosomes in vitro. 61
2044234 1991
25
Detection of Epstein-Barr virus genomes in archival tissues by polymerase chain reaction. 61
2163603 1990
26
Immunoproliferative disorders: detection, prevention, and therapeutics. 61
2508454 1989
27
Systemic vasculitis in association with human immunodeficiency virus infection. 61
2655605 1989
28
The clinical significance of pure Bence Jones proteinuria at low concentration. 61
2929504 1989
29
Immunoregulation in clinical diseases: an overview. 61
2642769 1989
30
The clinical spectrum of pure Bence Jones proteinuria. A study of 66 patients. 61
3179959 1988
31
Increased soluble interleukin-2 receptor levels in the sera of type 1 diabetic patients. 61
3265901 1988
32
Immunobeads test (antibody coated polyacrylamide beads) in the immunological characterization of lymphoproliferative disorders. 61
3502472 1987
33
Effects of long-term maintenance therapy with a new glucocorticoid, deflazacort, on mineral metabolism and statural growth. 61
3111667 1987
34
Light chains and the kidney. 61
3102562 1987
35
Monoclonal antibodies (Mabs) in head and neck cancer. 61
3534285 1986
36
Human T4+ lymphocytes produce a phagocytosis-inducing factor (PIF) distinct from interferon-alpha and interferon-gamma. 61
2416812 1986
37
Deregulation of immunoglobulin expression: is this the main cause of Burkitt's lymphoma? 61
4058028 1985
38
Association of lymphocytic neoplasia and mesothelioma. 61
3967191 1985
39
Study of cell-surface markers in chronic lymphocytic leukaemia (CLL). 61
6205953 1984
40
Study of the natural history of immunoblastic lymphadenopathy and atypical immunoproliferative disorders. 61
6667410 1983
41
A study of familial factors in Alzheimer's disease. 61
6212094 1982
42
[Clinical indications for monitoring immunologic reactivity (immune status)]. 61
6996352 1980
43
[Kinetic and immunological considerations on the therapy of immunoproliferative disorders]. 61
375339 1979
44
Cryopathic gangrene with an IgM lambda cryoprecipitating cold agglutinin. 61
101298 1978
45
Waldenström-like immunocytic lymphoma with IgG serum M component. 61
410217 1977
46
Monoclonal immunoglobulin disorders: a report of 154 cases. 61
820198 1976
47
Reticulum cell sarcoma of the cecum and macroglobulinemia: a case report. 61
817088 1976
48
The excretion of tryptophan metabolites in patients with different forms of haemoblastosis. 61
1244082 1975
49
Development of acute erythroleukemia in B-cell immunoproliferative disorders after prolonged therapy with alkylating drugs. 61
4216270 1974
50
Surface IgD in immunoproliferative disorders. 61
4218365 1974

Variations for Hypersensitivity Reaction Type Iv Disease

Expression for Hypersensitivity Reaction Type Iv Disease

Search GEO for disease gene expression data for Hypersensitivity Reaction Type Iv Disease.

Pathways for Hypersensitivity Reaction Type Iv Disease

Pathways related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 TNF SERPINA3 NOD2 IL6 IL2 IL10
2
Show member pathways
13.85 TNF IL6 IL2 IL10 FASLG FAS
3
Show member pathways
13.71 TNF IL6 IL2 IL10 IFNG FASLG
4
Show member pathways
13.45 TNF IL6 IL2 IL10 FASLG FAS
5
Show member pathways
13.4 TNF NOD2 IL6 IL2 IL10 IFNG
6
Show member pathways
13.3 TNF IL6 IL2 IL10 FASLG FAS
7
Show member pathways
13.24 TNF IL6 IL2 IL10 IFNG FASLG
8
Show member pathways
12.87 TNF IL6 IL2 IFNG FASLG FAS
9 12.82 TNF IL6 IFNG FASLG FAS
10
Show member pathways
12.81 TNF IL6 IL2 IL10 IFNG ICOSLG
11
Show member pathways
12.7 TNF IFNG FASLG FAS CD4
12
Show member pathways
12.68 TNF IL2 IL10 IFNG ICOSLG CD4
13
Show member pathways
12.66 TNF NOD2 IL6 IL2 IL10 IFNG
14
Show member pathways
12.65 TNF IL6 IL2 IL10 IFNG CD4
15 12.62 TNF IL2 IL10 IFNG FASLG FAS
16
Show member pathways
12.62 TNF IL6 IL2 IL10 IFNG FAS
17
Show member pathways
12.56 TNF IL2 IFNG FASLG FAS
18
Show member pathways
12.39 TNF IL6 IL2 IL10 CCR6
19
Show member pathways
12.39 TNF SERPINA3 IL6 IL2 IFNG CRP
20 12.36 TNF IL6 IL2 CD4
21
Show member pathways
12.35 TNF FASLG FAS CASP10
22
Show member pathways
12.31 TNF IL6 IL2 IL10 IFNG
23 12.3 TNF NOD2 IL6 IL10 IFNG CASP10
24
Show member pathways
12.26 TNF FASLG FAS CASP10
25
Show member pathways
12.25 TNF IL6 IL2 IL10
26
Show member pathways
12.24 TNF IFNG FASLG FAS
27
Show member pathways
12.24 TNF IL6 IFNG FASLG FAS
28 12.12 TNF IL6 IL2 IL10 CD8A CD4
29 12.06 TNF IL6 IL2 IFNG
30
Show member pathways
12.06 IL2 IFNG FASLG CD8A CD4
31 12.05 TNF NOD2 IL6 FAS CASP10
32 12.04 TNF IL6 IL2 IL10 IFNG CD8A
33 12.03 TNF IL6 IL10 FASLG
34 11.97 TNF IL6 IL10 IFNG
35 11.96 TNF IL6 CD8A CD4
36
Show member pathways
11.82 TNF IL2 IFNG FASLG
37
Show member pathways
11.81 TNF IL6 IL2 IL10 IFNG CD4
38 11.78 TNF IL6 IL10
39 11.75 TNF IL6 IL10 ICOSLG CCR6
40
Show member pathways
11.73 TNF IL6 IL2 IFNG
41
Show member pathways
11.71 TNF IL2 IFNG FASLG CD8A
42 11.62 TNF IL6 IL10 IFNG
43 11.6 TNF IL2 IL10 IFNG CD8A CD4
44 11.59 TNF IL6 IL2 IFNG FASLG FAS
45 11.58 TNF IL6 IL10
46 11.58 IL2 IL10 IFNG CD4
47 11.57 TNF IL6 IFNG FASLG
48 11.56 TNF IL2 IFNG
49 11.52 TNF FASLG FAS
50 11.41 TNF IL6 IL10

GO Terms for Hypersensitivity Reaction Type Iv Disease

Cellular components related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.9 TNF SERPINA3 IL6 IL2 IL10 IFNG
2 cell surface GO:0009986 9.73 TNF NOD2 FASLG FAS CD4 CCR6
3 extracellular space GO:0005615 9.65 TNF SERPINA3 MIR155 IL6 IL2 IL10
4 CD95 death-inducing signaling complex GO:0031265 9.32 FAS CASP10
5 external side of plasma membrane GO:0009897 9.28 TNF ICOSLG FASLG FAS CD8A CD4

Biological processes related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 10.1 IL2 IFNG ICOSLG CD8A CD4
2 response to lipopolysaccharide GO:0032496 9.96 NOD2 MIR155 IL10 FASLG
3 cellular response to lipopolysaccharide GO:0071222 9.96 TNF NOD2 IL6 IL10
4 positive regulation of protein phosphorylation GO:0001934 9.92 TNF IL2 IFNG FAS CD4
5 defense response to Gram-positive bacterium GO:0050830 9.9 TNF NOD2 IL6 CRP
6 regulation of insulin secretion GO:0050796 9.87 TNF IL6 IFNG
7 negative regulation of interleukin-6 production GO:0032715 9.87 TNF MIR155 IL10
8 positive regulation of inflammatory response GO:0050729 9.87 TNF MIR155 IL2 IFNG
9 response to glucocorticoid GO:0051384 9.86 TNF IL6 IL10
10 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.86 TNF FASLG FAS CASP10
11 positive regulation of interleukin-8 production GO:0032757 9.85 TNF NOD2 IL6
12 positive regulation of cytokine production GO:0001819 9.85 TNF IL10 IFNG
13 positive regulation of interleukin-6 production GO:0032755 9.85 TNF NOD2 IL6 IFNG
14 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.85 TNF NOD2 FASLG CD4 CASP10
15 positive regulation of phagocytosis GO:0050766 9.82 TNF NOD2 IFNG
16 T cell activation GO:0042110 9.82 ICOSLG CD8A CD4
17 positive regulation of interleukin-12 production GO:0032735 9.81 NOD2 MIR155 IFNG
18 positive regulation of chemokine production GO:0032722 9.81 TNF IL6 IFNG
19 acute-phase response GO:0006953 9.8 SERPINA3 IL6 CRP
20 apoptotic signaling pathway GO:0097190 9.8 TNF FASLG FAS CASP10
21 cytokine-mediated signaling pathway GO:0019221 9.8 TNF IL6 IL2 IL10 FASLG CD4
22 positive regulation of JAK-STAT cascade GO:0046427 9.79 TNF IL6 IL10
23 positive regulation of activated T cell proliferation GO:0042104 9.78 MIR155 IL2 ICOSLG
24 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.78 TNF IL6 IL2 IFNG
25 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.75 TNF NOD2 IL6
26 positive regulation of T cell proliferation GO:0042102 9.73 IL6 IL2 CD4 BTNL2
27 positive regulation of immunoglobulin production GO:0002639 9.71 IL6 IL2 IL10
28 humoral immune response GO:0006959 9.71 TNF IL6 IFNG CCR6
29 neutrophil mediated immunity GO:0002446 9.7 IL6 ACE
30 negative regulation of vascular wound healing GO:0061044 9.69 TNF MIR155
31 positive regulation of interleukin-17 production GO:0032740 9.69 NOD2 IL6 IL2
32 negative regulation of bicellular tight junction assembly GO:1903347 9.68 TNF MIR155
33 endothelial cell apoptotic process GO:0072577 9.68 TNF IL10
34 response to peptidoglycan GO:0032494 9.68 NOD2 IL6
35 vascular endothelial growth factor production GO:0010573 9.68 TNF IL6
36 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.67 TNF NOD2
37 positive regulation of interleukin-1 beta production GO:0032731 9.67 TNF NOD2 IL6 IFNG
38 negative regulation of cytokine production involved in immune response GO:0002719 9.66 TNF IL10
39 negative regulation of interleukin-18 production GO:0032701 9.65 NOD2 IL10
40 positive regulation of plasma cell differentiation GO:1900100 9.62 IL2 IL10
41 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.62 TNF IFNG
42 positive regulation of vitamin D biosynthetic process GO:0060557 9.59 TNF IFNG
43 positive regulation of nitrogen compound metabolic process GO:0051173 9.58 TNF IFNG
44 extrinsic apoptotic signaling pathway GO:0097191 9.46 TNF IFNG FASLG FAS
45 negative regulation of lipid storage GO:0010888 9.43 TNF IL6 CRP
46 immune response GO:0006955 9.32 TNF IL6 IL2 IL10 IFNG FASLG
47 necroptotic signaling pathway GO:0097527 9.13 TNF FASLG FAS

Molecular functions related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.1 TNF IL6 IL2 IL10 IFNG FASLG

Sources for Hypersensitivity Reaction Type Iv Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....